Research Analysts Issue Forecasts for VRTX FY2026 Earnings

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Analysts at Erste Group Bank upped their FY2026 earnings estimates for shares of Vertex Pharmaceuticals in a research note issued on Wednesday, July 15th. Erste Group Bank analyst H. Engel now forecasts that the pharmaceutical company will post earnings of $16.93 per share for the year, up from their previous forecast of $16.91. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $17.01 per share. Erste Group Bank also issued estimates for Vertex Pharmaceuticals’ FY2027 earnings at $18.97 EPS.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share for the quarter, beating the consensus estimate of $4.24 by $0.23. The company had revenue of $2.99 billion during the quarter, compared to the consensus estimate of $2.99 billion. Vertex Pharmaceuticals had a net margin of 35.51% and a return on equity of 23.86%. Vertex Pharmaceuticals’s revenue was up 8.3% compared to the same quarter last year. During the same period last year, the firm earned $4.06 earnings per share.

VRTX has been the subject of a number of other research reports. Canaccord Genuity Group lowered their price objective on Vertex Pharmaceuticals from $437.00 to $436.00 and set a “hold” rating for the company in a research report on Tuesday, May 5th. Wall Street Zen cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, June 28th. UBS Group raised their price target on Vertex Pharmaceuticals from $545.00 to $585.00 and gave the stock a “buy” rating in a report on Monday. Morgan Stanley boosted their price target on Vertex Pharmaceuticals from $612.00 to $616.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 5th. Finally, Barclays upped their price objective on shares of Vertex Pharmaceuticals from $607.00 to $615.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Twenty-one research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $559.61.

Vertex Pharmaceuticals Trading Down 0.1%

Shares of VRTX stock opened at $485.65 on Friday. Vertex Pharmaceuticals has a 12-month low of $362.50 and a 12-month high of $533.67. The business’s fifty day simple moving average is $462.54 and its 200-day simple moving average is $459.00. The company has a market cap of $123.26 billion, a PE ratio of 28.80, a PEG ratio of 2.11 and a beta of 0.29.

Insider Buying and Selling

In other news, EVP Joy Liu sold 1,104 shares of the business’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $425.02, for a total value of $469,222.08. Following the completion of the transaction, the executive vice president owned 20,729 shares of the company’s stock, valued at $8,810,239.58. The trade was a 5.06% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Duncan Mckechnie sold 1,541 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $519.00, for a total value of $799,779.00. Following the sale, the executive vice president directly owned 11,001 shares in the company, valued at approximately $5,709,519. This trade represents a 12.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 18,874 shares of company stock valued at $8,707,966 in the last 90 days. 0.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Vertex Pharmaceuticals

Several hedge funds have recently bought and sold shares of VRTX. Community Financial Services Group LLC purchased a new position in Vertex Pharmaceuticals in the second quarter valued at $26,000. Motiv8 Investments LLC acquired a new position in shares of Vertex Pharmaceuticals in the fourth quarter worth about $26,000. Elevation Wealth Partners LLC boosted its stake in shares of Vertex Pharmaceuticals by 103.7% during the 2nd quarter. Elevation Wealth Partners LLC now owns 55 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 28 shares in the last quarter. Swiss RE Ltd. purchased a new stake in shares of Vertex Pharmaceuticals during the 4th quarter worth about $28,000. Finally, Eagle Bay Advisors LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 4th quarter valued at about $29,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.